Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Appropriate Dosing to Optimise Personalised Cancer Treatments

NCT04154163 is registered in ClinicalTrials.gov with University of Dundee as lead sponsor.

NCT NCT04154163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04154163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Appropriate Dosing to Optimise Personalised Cancer Treatments
Lead sponsor
University of Dundee
Phase
Observational
Overall status
Completed
Start date
January 10, 2020
Completion date
March 5, 2021
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-small cell, melanoma stage iii, melanoma stage iv, ovarian cancer, renal cancer stage iii, renal cancer stage iv